Novolyze Funding: How Much Did They Raise & Key Investors

How Much Did Novolyze Raise?
Funding & Key Investors

Novolyze has solidified its position within the food safety technology sector, securing a total capital infusion of $18.4M. This trajectory of financial backing, punctuated by a recent strategic investment of $678K, underscores the market's growing demand for rigorous microbial validation solutions. By consistently attracting institutional interest, the firm has transitioned from its early-stage roots into a critical player supporting global food supply chain integrity.

The company's ability to navigate complex regulatory landscapes, particularly regarding FSMA requirements, has been a primary driver of its sustained growth. As the industry shifts toward more stringent safety protocols, Novolyze remains at the forefront, leveraging its specialized R&D capabilities to provide essential surrogate microorganisms that facilitate plant validation studies.

What is Novolyze?

Novolyze

Business Services

Software Testing

Founded in 2012, Novolyze operates as a specialized biotechnology firm dedicated to the development and manufacturing of ready-to-use surrogate microorganisms. These proprietary tools are instrumental for food manufacturers aiming to validate their processing systems and ensure compliance with international safety standards. With a sophisticated R&D center based in France, the company integrates BSL2 laboratory environments with advanced bio-production facilities and lab-scale pilot units. This infrastructure allows Novolyze to simulate real-world food processing conditions, providing clients with actionable data that mitigates risk and enhances operational safety across the food production lifecycle.

How much funding has Novolyze raised?

Novolyze has raised a total of $18.4M across 3 funding rounds:

2018

Angel/Seed

$2.7M

2022

Series A

$15M

2026

Stock/Share Issuance

$678K

Angel/Seed (2018): $2.7M, investors not publicly disclosed

Series A (2022): $15M led by WAVE Equity Partners

Stock/Share Issuance (2026): $678K, investors not publicly disclosed

Key Investors in Novolyze

WAVE Equity Partners

WAVE Equity Partners is a growth equity firm focused on ESG impact, backing sustainable enterprises that drive industrial efficiency and resource conservation.

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for Novolyze?

With the recent influx of capital, Novolyze is well-positioned to scale its industrial footprint and expand its reach within the global food safety market. The strategic focus will likely center on deepening its R&D pipeline to address emerging pathogens and evolving regulatory frameworks. By scaling its bio-production capacity, the company aims to meet the increasing demand for standardized validation tools, effectively cementing its role as an indispensable partner for large-scale food enterprises. Future growth will likely involve further integration into automated food safety management systems, ensuring that Novolyze remains a cornerstone of the modern food safety ecosystem.

See full Novolyze company page

See More Financial Insights